CatalystMarker
← board

APRE

Marea Therapeuticsdistress 6/10 · elevated risk
$0.66+1%today-68% from 52w high
aprea.com8 employeesDoylestown, PABiotechnology
Lead: advanced solid tumors
Revenue
pre-revenue
Liquidity
$46M
Runway
3.9 yrs
Shares 1y
+113%

Price & events

-21.6% over 6M
$0.59$0.79$1.00Jan 26Apr 26Jul 26109.8Mdilution: 424B7 offering (2026-05-15)dilution: EFFECT shelf_effective (2026-04-29)dilution: 424B3 offering (2026-04-29)dilution: S-3 shelf_registration (2026-04-22)dilution: EFFECT shelf_effective (2026-03-19)dilution: 424B3 offering (2026-03-19)dilution: S-3/A shelf_registration (2026-03-17)dilution: S-3 shelf_registration (2026-02-20)financing: 8-K private_placement (2026-03-30)financing: 8-K private_placement (2026-01-29)catalyst: PHASE2 MAR001 (2026-07-01) — click to opencatalyst: PHASE2 MAR001 (2026-07-01) — click to opencatalyst: PHASE1 APR-1051 (2026-06-30) — click to opencatalyst: PHASE1,PHASE2 ATRN-119 (2026-06-30) — click to opencatalyst: PHASE1 APR-1051 (2026-06-30) — click to opencatalyst: PHASE1 APR-1051 (2026-06-30) — click to opencatalyst: PHASE1 APR-1051 (2026-06-30) — click to opencatalyst: PHASE1 ATRN-119 (2026-06-30) — click to opencatalyst: PHASE1 APR-1051 (2026-05-30) — click to openrating: Wedbush: Outperform (2026-05-14)rating: Oppenheimer: Outperform (2026-05-07)rating: Wedbush: Outperform (2026-03-31)rating: HC Wainwright & Co.: Buy (2026-03-31)rating: Wedbush: Outperform (2026-02-10)rating: HC Wainwright & Co.: Buy (2026-01-29)
CatalystRating changeDilutionFinancingdashed = today
+1.2%
1D
-5.4%
1W
-16.9%
1M
-30.5%
3M
-21.6%
6M
-68.3%
1Y
-83.4%
2Y
-99.2%
5Y
-99.3%
All

Overview

Market Cap
$8.17M
Volume
24.50K
52 Week Range
$0.59 – $2.08
Total Shares
12.38M
Float Shares
7.41M
Short %
0.67%
% Held by Insiders
13.46%
% Held by Institutions
18.13%
RVOL
0.27x
Beta
1.56

Pipeline stages · 4 programs

APR-1051
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-06
MAR002
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-08
ATRN-119
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-02
MAR001
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved

Pipeline · 5 trials · 3 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2027-06
Estimated 50%
readout ~2027-07-01
Phase 1APR-1051Advanced Solid Tumor—recruiting
2027-08
Estimated 50%
readout ~2027-09-15
Phase 2MAR002Acromegaly—not yet recruiting
2028-02
Estimated 50%
readout ~2028-03-17
Phase 1/2ATRN-119Advanced Solid Tumor—active not recruiting
2026-07-01
Phase 2MAR001Hypertriglyceridemia—active not recruiting
2026-07-01
Phase 2MAR001Hypertriglyceridemia—recruiting

Catalyst news & presentations · 10

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 12,382,776 · 4 offerings/1y · 3 PIPEs
  • 2026-05-15424B7offering
  • 2026-04-29424B3offering
  • 2026-04-29EFFECTshelf_effective
  • 2026-04-22S-3shelf_registration
  • 2026-03-308-Kprivate_placement
  • 2026-03-19424B3offering
  • 2026-03-19EFFECTshelf_effective
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

strong buy · target $4 (+552% upside) · 4 analysts
  • 2026-05-14WedbushOutperform
  • 2026-05-07OppenheimerOutperform
  • 2026-03-31WedbushOutperform
  • 2026-03-31HC Wainwright & Co.Buy
  • 2026-02-10WedbushOutperform
  • 2026-01-29HC Wainwright & Co.Buy

Competitors — advanced solid tumors

  • ABBVAbbVie Inc.$451.1B · D2
  • MRKMerck & Co., Inc.$318.8B · D3
  • NVSEFNOVARTIS AG$292.0B · D3
  • AMGNAMGEN INC$195.4B · D3
  • RVMDRevolution Medicines, Inc.$40.3B · D1
  • CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
  • CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
  • BCYCBICYCLE THERAPEUTICS PLC$124M · D4
  • XLOXilio Therapeutics, Inc.$50M · D1

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.